NCT04267497View on ClinicalTrials.gov

Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study)

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 18, 2019

Primary Completion Date

November 10, 2022

Study Completion Date

November 10, 2022

Conditions
Invasive Pulmonary Aspergillosis
Interventions
DRUG

Amphotericin B Liposomal 50 MG

Amphotericin B 50 mg powder for infusion diluted in 12 ml of sterile water. It will be administered by nebulized route 25 mg (6 ml), 3 times a week, for 6 weeks.

OTHER

Placebo

Sterile water for injection. It will be administered by nebulized route: 6 ml, 3 times a week for 6 weeks.

Trial Locations (1)

28760

Jesus Fortun, Madrid

All Listed Sponsors
lead

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

OTHER

NCT04267497 - Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study) | Biotech Hunter | Biotech Hunter